Cemiplimab for Kidney Transplant Recipients With Cutaneous Squamous Cell Carcinoma
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have ...
1. There was no kidney rejection noted in the cemiplimab for kidney transplant recipients. 2. Cemiplimab was found to have ...
1. After neoadjuvant treatment with celmiplimab, half of the patients were found to have a complete pathological response 2. Almost ...
1. Overall survival is longer in patients treated with cemiplimab as compared to chemotherapy. 2. Fewer adverse effects are associated ...
Click to read the study in The Lancet Oncology.
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with cemiplimab ...
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.